This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于“BL-B01D1+PD-1单抗±化疗”治疗多种晚期实体瘤获得7个II期临床试验批准通知书的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that “BL-B01D1+PD-1 monoclonal antibody ± chemotherapy” has obtained approval notices for 7 phase II clinical trials to treat various advanced solid tumors
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.